CRP and cystic fibrosis: Our results suggest that use of CF at a daily dose as low as 112 mg for 30 days may significantly reduce levels of the pro-inflammatory and pro-atherogenic markers TC, LDL cholesterol, triglycerides, CRP, and homocysteine, while increasing the levels of HDL cholesterol, which is considered a protective lipid.